Cargando…
A Randomized Controlled Trial of Anti-TNF α Bio-similar Adalimumab vs. Prednisolone in the Management of Leprosy Patients with New Type 1 Lepra Reaction
BACKGROUND: Leprosy Type 1 (T1R) reactions are immune-mediated events leading to nerve damage and preventable disability affecting hands, feet and eyes. TNF-α is the main inflammatory cytokine associated. Type 1 Reactions are treated with oral corticosteroids. There is little evidence on alternative...
Autor principal: | Mitra, Debdeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631132/ http://dx.doi.org/10.1093/ofid/ofx163.1805 |
Ejemplares similares
-
1356. A Randomized Controlled Trial of Prednisolone vs. TNF-α inhibitor Infliximab in the Management of Type 1 Lepra Reaction in Leprosy Patients
por: Chopra, Ajay, et al.
Publicado: (2019) -
811. A Randomized Controlled Trial of Prednisolone vs. Interleukin 17 A Inhibitor Secuinumab in the Management of Type 1 Lepra Reaction in Leprosy Patients
por: Mitra, Debdeep
Publicado: (2018) -
Rare Atypical Presentations in Type 2 Lepra Reaction: A Case Series
por: Mitra, Debdeep
Publicado: (2017) -
Type I Lepra Reaction as the Presenting Sign of Histoid Leprosy
por: Sun, Jingru, et al.
Publicado: (2017) -
Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to phenolic glycolipid-1, lipoarabinomanan, ceramide and S100-B
por: Raju, Renuka, et al.
Publicado: (2014)